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Abstract
Background. Elevated cardiac troponin (cTn) levels have
been reported to predict adverse cardiovascular outcomes
in asymptomatic ESRD patients. However, the prognos-
tic value of elevated cTn levels associated with sepsis in
ESRD patients is unknown. Therefore, this study aimed to
elucidate the clinical implications of elevated cTnI levels
in ESRD patients with sepsis.
Methods. Of the 305 ESRD patients in whom cTnI was
measured between January 2003 and December 2005, sep-
sis developed in 121 patients during follow-up. Based on
cTnI levels at the onset of sepsis, patients were classified
as elevated cTnI group (ET, n = 50, >0.2 ng/ml) and lower
cTnI group (LT, n = 71, ≤0.2 ng/ml). Study endpoints
were short- and long-term mortality. Short-term mortality
was defined as death occurring within 90 days after sepsis,
and patients who survived during this period were followed
till death after 90 days.
Results. Before sepsis, the median concentration of cTnI
was 0.05 (0.01–3.59) ng/ml and it was significantly in-
creased to 0.11 (0.01–22.0) ng/ml when sepsis supervened
(P< 0.01). Compared to the LT group, the short-term mor-
tality rate was significantly higher in the ET group (P <
0.05). After adjustment for age, diabetes, serum albumin
and CRP levels, presence of shock and previous cardiovas-
cular disease history, the ET group had a greater odds ratio
of short-term mortality (OR 5.13, P < 0.01). In addition,
the Kaplan–Meier plot for long-term survival revealed a
significantly higher mortality rate in the ET group. In a
multivariate Cox regression analysis, the elevation of cTnI
levels was an independent determinant for long-term mor-
tality (HR 5.90, P < 0.01).
Conclusion. This study showed that elevated cTnI levels
were significantly associated with short- and long-term
mortality in ESRD patients with sepsis. Therefore, elevated
cTnI levels in these patients should not be overlooked and
be followed for adverse outcomes.
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Introduction
Cardiovascular events and infection are the leading causes
of death in patients with end-stage renal disease (ESRD)
[1]. It is generally accepted that inflammation has an impor-
tant role not just in the pathogenesis of atherosclerosis but
also in the initiation of acute coronary syndrome (ACS) [2].
Uraemia per se is considered as chronicmicroinflammatory
status, and inflammatory markers have been demonstrated
to be independent predictors in dialysis patients [3]. Sepsis
is also an inflammatory state and may exert a synergistic
effect on inflammation and atherosclerosis. In the general
population, acute lower respiratory infection and acute uri-
nary tract infection were associated with an increase in
myocardial infarction or stroke [4]. In addition, sepsis with
bacteraemia was associated with cardiovascular morbidity
and mortality in patients with ESRD [5]. Cardiac troponins
(cTns) are biomarkers that are previously introduced for
diagnosis and risk stratification in patients with ACS [6].
Serum cTn levels are elevated in 31–85% of critically ill
patients with sepsis [7,8]. The elevation of cTn levels ac-
companied by sepsis and septic shock has been reported
to be associated with left ventricular dysfunction and poor
prognosis in the general population [8,9].
Elevated cTn levels are common in asymptomatic ESRD
patients, but their prognostic value is still under debate be-
cause it is often elevated in the setting of even mild degrees
of renal failure without ACS [10]. Several studies revealed
a low specificity of cTn for the assessment of ACS in dialy-
sis patients [11,12]. Despite these limitations, elevated cTn
levels were predictive for cardiovascular events and mortal-
ity in asymptomatic ESRD patients [13–15]. However, their
prognostic value combined with sepsis in ESRD patients is
currently unknown. Therefore, we undertook this study to
elucidate the clinical implications of elevated cTnI levels
in asymptomatic ESRD patients with sepsis.
Patients and methods
Study population and data collection
This is an observational cohort study with 305 ESRD
patients who had been treated with haemodialysis (HD)
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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or peritoneal dialysis (PD) between January 2003 and
December 2005. During this period, cTnI concentrations
were measured as a surveillance test for cardiovascular risk
assessment. These patients were followed, and sepsis de-
veloped in 127 patients. Of these, six patients in whom
cardiovascular events occurred during the follow-up period
were excluded. Therefore, a total of 121 patients were in-
cluded in the analysis. All patients were older than 18 years
and were maintained on dialysis therapy for >3 months.
Sepsis is defined as the systemic inflammatory response to
infection. In association with infection, it is manifested by
two or more of the following conditions: (1) temperature
>38◦C or <36◦C; (2) heart rate >90 beats/min; (3) respi-
ratory rate >20 breaths/min or PaO2 <32 mmHg and (4)
white blood cell (WBC) count >12 000/mm3, <4000/mm3
or >10% immature (band) forms.
Demographic data and clinical parameters were collected
with a retrospective review of medical records: age, gender,
diabetes, dialysis modality, dialysis duration, previous car-
diovascular disease (CVD) history, primary cause of sepsis,
bacteraemia and presence of septic shock. Septic shock was
defined as acute circulatory failure (systolic blood pressure
<90 mmHg, mean arterial pressure <65 mmHg or a re-
duction in systolic blood pressure <40 mmHg from the
baseline) despite adequate volume resuscitation. In addi-
tion, baseline laboratory data forWBCcount, haemoglobin,
platelet count, serum albumin, C-reactive protein (CRP),
CK-MB and cTnI were collected at the onset of sepsis.
Measurement of cTnI concentrations
The cTnI levels were measured by means of a one-
step enzyme immunoassay based on the sandwich prin-
ciples (AccuTnI, Beckman Coulter, Inc., USA). The
detection limit was 0.01 mg/l, and there was an interassay
coefficient of variation of 10% at 0.06 ng/ml. As described
above, we obtained data for cTnI that were measured be-
fore sepsis as well as at the onset of sepsis. The mean
duration between the two periods was 11.2 ± 8.9 months.
Patients were divided into elevated cTnI group (ET, n= 50,
>0.2 ng/ml) and lower cTnI group (LT, n= 71,≤0.2 ng/ml)
according to cTnI levels at the onset of sepsis.
Study endpoints
The date and cause of death were obtained by reviewing the
hospital records. Study endpoints were short- and long-term
mortality. Short-term mortality was defined as all-cause
death occurring within 90 days after the onset of sepsis.
Patients who survived during this period were followed for
the development of death from any cause after 90 days, and
these patients were subjected to long-term survival anal-
ysis. In addition, cardiovascular deaths that were caused
by myocardial infarction, congestive heart failure or sud-
den cardiac death were further assessed for the long-term
survival analysis.
Statistical analysis
All data were expressed as mean ± SD; however, data with
skewed distribution were expressed as median with range.
Table 1. Patient characteristics
Number of patients 121
Age (years) 66.1 ± 11.8
Sex (male/female) 53/68
DM, n (%) 82 (67.8%)
Dialysis duration (months) 25.3 ± 28.3
Dialysis modality (HD/PD) 61/60
Previous CVD history, n (%) 33 (27.2%)
CAOD, n (%) 22 (18.0%)
CVA, n (%) 17 (13.9%)
SBP (mmHg) 137.5 ± 34.7
DBP (mmHg) 77.1 ± 18.0
MAP (mmHg) 97.3 ± 27.4







Bacteraemia, n (%) 48 (39.7%)
WBC (/mm3) 11 591 ± 5942
Haemoglobin (g/dl) 9.6 ± 1.7
Serum albumin (g/dl) 2.6 ± 0.7
Platelet (×103/mm3) 194 ± 95
CRP (mg/dl) 10.04 ± 8.89
cTnI (ng/ml) 0.11 (0.01–22.0)a
CK-MB (ng/ml) 1.7 (0.50–191)a
DM, diabetes; CVD, cardiovascular disease; CAOD, coronary artery oc-
clusive disease; CVA, cerebrovascular attack; SBP, systolic blood pressure;
DBP, diastolic blood pressure; MAP, mean artery pressure; UTI, urinary
tract infection; CAPD, continuous ambulatory peritoneal dialysis; CRP, C-
reactive protein; HD, haemodialysis; PD, peritoneal dialysis; WBC, white
blood cells.
Data were expressed as mean ± SD.
aThese data were expressed as median with range
The comparisons between the two groups were made by
Student’s t-test and chi-square test. For analysis of short-
term mortality, logistic regression analysis was used. The
patient survival was analysed by Kaplan–Meier survival
analysis, and Cox proportional hazards regression models
were used to determine relationships between cTnI levels
and long-termmortality outcome.Covariateswith aP-value
of<0.10 in univariate analyses were subjected to multivari-
ate Cox regression analysis. Hazard ratios (HR) and 95%
confidence intervals (CI) for long-term mortality were ob-
tained. All probabilities were two tailed, and the level of
significance was set at 0.05. All analyses were conducted
using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Table 1 details clinical characteristics of the 121 patients.
Themean age was 66 years, and 43.8%weremale. Diabetes
(67.8%) was the most common cause of ESRD. The mean
dialysis duration was 25.3 ± 28.2 (range 3–148) months,
and the mean follow-up duration was 19.1 ± 18.9 months.
Of the subjects, 61 patients were treated with HD and 60
with PD. A previous CVD history was present in 33 patients
(27.2%): 22 patients (18.2%) with coronary artery disease
and congestive heart failure and 17 patients (14.1%) with
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Fig. 1. Changes of cTnI levels from the first measurement of cTnI to the
onset of sepsis. Prior to the onset of sepsis, the median concentration of
cTnI was 0.05 (0.01–3.59) ng/ml and it was significantly increased to 0.11
(0.01–22.0) ng/ml when sepsis supervened.
was pneumonia (66.1%) followed by urinary tract infection
(11.6%). Forty-eight patients (39.7%) had bacteraemia, and
septic shock was evident in 30 patients (24.8%). The most
common causative micro-organismwas staphylococcus au-
reus (28.3%).
Change of cTnI levels with sepsis
Before sepsis, the median concentration of cTnI was 0.05
(0.01–3.59) ng/ml and it was significantly increased to 0.11
(0.01–22.0) ng/ml when sepsis supervened (Figure 1, P <
0.01). Elevated cTnI levels at the onset of sepsis compared
to the levels before sepsiswere found in 88 patients (72.7%),
and cTnI levels >0.2 ng/ml were observed in 50 patients
(41.3%).
Comparison between patients with elevated cTnI levels
and those with lower cTnI levels
When the patients were divided into the two groups on the
basis of cTnI concentrations at the onset of sepsis, there
were no significant differences in age, gender, diabetes,
previous history of CVD, dialysis duration, dialysis modal-
ity, blood pressure, mean arterial pressure and incidence of
bacteraemia between the two groups (Table 2). However,
patients with elevated cTnI levels had lower serum albu-
min levels (2.4 ± 0.7 versus 2.7 ± 0.6 g/dl, P < 0.05) and
had higher CRP levels (12.6 ± 8.4 versus 8.3 ± 8.8 mg/dl,
P < 0.01) and CK-MB levels (15.5 ± 34.0 versus 2.1 ±
2.1 mg/dl, P < 0.01) compared to those with lower cTnI
levels. Also, septic shock was less common in patients
with elevated cTnI levels (12.0% versus 33.8%, P < 0.05)
(Table 2).
Elevated cTnI levels and short-term mortality
A total of 55 deaths occurred within 90 days after the onset
of sepsis. Forty-four and seven deaths were attributable to
sepsis and cardiovascular events, respectively. The mortal-
ity rate (60.0% versus 35.2%, P < 0.01) was significantly
higher in patients with elevated cTnI levels compared to
those with lower cTnI levels. In addition, patients with el-
evated cTnI levels had a greater odds of death [odds ratio
Table 2. Comparison between patients with elevated cTnI (ET) and those
with lower cTnI (LT) levels
LT group (n = 71) ET group (n = 50)
Age (years) 66 ± 12 67 ± 12
Sex (male/female) 31/40 22/28
DM, n (%) 44 (62.0%) 38 (76.0%)
Dialysis duration (months) 28 ± 32 22 ± 24
Dialysis modality (HD/PD) 40/31 21/29
Previous CVD history, n (%) 17 (23.9%) 16 (32%)
CAOD, n (%) 11 (15.5%) 11 (22.0%)
CVA, n (%) 8 (11.3%) 8 (16.0%)
SBP (mmHg) 139.3 ± 34.3 135.0 ± 35.4
DBP (mmHg) 77.3 ± 18.6 76.8 ± 17.5
MAP (mmHg) 98.0 ± 22.4 96.2 ± 22.6
Septic shock, n (%) 24 (33.8%) 6 (12.0%)‡
Bacteraemia, n (%) 28 (39.4%) 20 (40.0%)
WBC (/mm3) 10 750 ± 5307 12 776 ± 6548
Haemoglobin (g/dl) 9.9 ± 1.6 9.3 ± 1.6
Platelet (×103/mm3) 199 ± 100 187 ± 89
Serum albumin (g/dl) 2.8 ± 0.6 2.5 ± 0.7†
CRP (mg/dl) 8.3 ± 8.8 12.5 ± 8.4‡
cTnI (ng/ml)a 0.04 (0.01–0.19) 0.80 (0.21–22.0)‡
CK-MB (ng/ml)a 1.50 (0.50–9.40) 5.15 (0.50–191.0)‡
DM, diabetes; HD, haemodialysis; PD, peritoneal dialysis; CVD, cardio-
vascular disease; CAOD, coronary artery occlusive disease; CVA, cere-
brovascular attack; SBP, systolic blood pressure; DBP, diastolic blood
pressure; MAP, mean artery pressure; WBC, white blood cells; CRP,
C-reactive protein.
aThese data were expressed as median with range.
†P < 0.05, ‡P< 0.01 versus the LT group.
Table 3. Multivariate logistic regression analysis for short-termmortalitya
OR 95% CI P-value
Age (per 1-year increase) 1.05 1.03–1.14 0.001
DM (versus non-DM) 3.00 1.09–8.25 0.033
Previous CVD history (versus none) 1.05 0.36–3.03 0.928
Septic shock (versus none) 8.00 2.21–28.94 0.002
Serum albumin (per 1 g/dl increase) 0.17 0.07–0.41 <0.001
CRP (per 1 mg/dl increase) 1.02 0.97–1.08 0.406
Elevated cTnI levels (versus ≤0.2 ng/ml) 5.13 1.73–15.18 0.003
aAdjusted for age, diabetes, previous CVD history, presence of septic
shock, serum albumin and CRP levels and elevated cTnI levels.
(OR) 5.13, 95% CI 1.73–15.18, P < 0.01] in a multivari-
ate logistic regression analysis adjusted for age, diabetes,
previous CVD history, presence of septic shock, and serum
albumin and CRP levels (Table 3). Besides cTnI, other fac-
tors that predicted the short-term mortality were old age
(per 1-year increase, OR 1.05, 95% CI 1.03–1.14, P =
0.001), presence of diabetes (OR 3.00, 95% CI 1.09–8.25,
P= 0.033) and septic shock (OR 8.00, 95% CI 2.21–28.94,
P = 0.002), and lower serum albumin levels (per 1 g/dl
increase, OR 0.17, 0.07–0.41, P < 0.001).
Elevated cTnI levels and long-term mortality
The relationship between cTnI levels and long-termmortal-
ity was further assessed in 66 patients who survived sepsis
and other complications during 90 days after the onset of
sepsis. Of the patients, 20 patients (30.3%) were in the ET
group and the remaining 46 (69.7%) in the LT group. A



















Elevated cTnI in ESRD patients with sepsis 1571
Fig. 2. Kaplan–Meier survival curve for long-term all-cause mortality
(A) and cardiovascular mortality (B). The patient survival rate was sig-
nificantly lower (P < 0.01) and cumulative cardiovascular mortality was
significantly higher (P < 0.05) in patients with elevated cTnI levels com-
pared to those with lower cTnI levels.
Table 4. Multivariate Cox proportional hazard models for long-term
adverse outcomes
HR 95% CI P-value
All-cause mortalitya
Age (per 1-year increase) 1.04 1.00–1.08 0.050
DM (versus non-DM) 2.38 0.87–6.50 0.090
Previous CVD history (versus none) 3.57 1.28–9.94 0.015
Septic shock (versus none) 2.98 0.87–10.25 0.083
CRP (per 1 mg/dl increase) 0.99 0.93–1.05 0.620
Elevated cTnI levels (versus ≤0.2 ng/ml) 5.90 2.06–16.87 0.001
Cardiovascular mortalityb
Age (per 1-year increase) 1.01 0.96–1.06 0.674
Diabetes (versus non-DM) 0.95 0.18–5.08 0.952
Previous CVD history (versus none) 6.01 1.43–25.19 0.014
Elevated cTnI levels (versus ≤0.2 ng/ml) 5.17 1.16–23.16 0.032
aAdjusted for age, diabetes, previous CVD history, presence of septic
shock, serum CRP levels and elevated cTnI levels.
bAdjusted for age, diabetes, previous CVD history and elevated cTnI
levels.
the ET group had a significantly higher mortality rate than
those in the LT group (55.0% versus 23.9%, P < 0.05).
The Kaplan–Meier plot for long-term survival revealed that
patient survival was significantly lower in patients with el-
evated cTnI levels (Figure 2A, P < 0.01). In addition, in a
multivariate Cox regression analysis adjusted for age, dia-
betes, presence of septic shock, previous CVD history and
serum CRP levels, patients in the ET group had a higher
risk of death (HR 5.90, 95% CI 2.06–16.9, P < 0.01) com-
pared to those in the LT group (Table 4). For long-term
cardiovascular mortality 90 days after the onset of sepsis,
the elevation of cTnI levels was identified as a significant
determinant (HR 5.17, 95% CI 1.16–23.2, P < 0.05) af-
ter adjustment of age, diabetes and previous CVD history
(Figure 2B, Table 4).
Discussion
Recently, the importance of cardiac biomarkers has been
highlighted because CVDs are the most common cause of
death in ESRD patients [13,16]. CTnT and cTnI are two
of the clinically available biomarkers whose clinical value
has been validated not only in non-CKD patients but also
in CKD patients [13]. Although a number of literatures
have reported that the elevated cTn level is an independent
predictor of cardiovascular events and mortality in ESRD
patients [13–18], its utility in this population with septic
condition has never been demonstrated. This study showed
that sepsis could trigger or aggravate myocardial injury,
and the elevated cTnI level associated with sepsis was a
significant determinant of short- and long-term adverse
outcomes in ESRD patients.
The elevated cTnT level as a risk factor for sepsis-related
death in patients undergoing HD was previously suggested
byHocher et al. [19]. Theymeasured the cTnT level at base-
line and followed the patients for 2 years after blood sam-
pling. Interestingly, in that study, the elevated cTnT level at
baseline was already predictive of sepsis-related mortality
later on. The authors did not give a clear explanation on
why such cardiac biomarker measured even when sepsis
was not evident could predict infection-related adverse out-
comes. In contrast, our study revealed that the elevated cTnI
level at the onset of sepsis was a significant determinant of
sepsis-related mortality whereas its level at the study entry
was not (data not shown). It should be noted that our study
is different from the study by Hocher et al. in that they
did not provide change of cTnT level because cTnT was
measured only once at baseline. We clearly showed change
of cTnI level by measuring it both at the study entry and at
the onset of sepsis. Therefore, it is reasonable to presume
that the cTnI levels were significantly affected by sepsis.
In addition, cTnI levels >0.2 ng/ml measured at the study
entry were observed in only 6% of patients. This may give
low statistical power to predict adverse outcomes. Whether
cTn measured prior to sepsis can predict infection-related
death later on remains to be further investigated.
Among many other cardiac biomarkers that can predict
adverse outcomes, such as CRP, interleukin-6, intercellular
adhesion molecule-1, etc, cTnI is of our special interests
because such markers are nonspecific in the inflamma-
tory process and can be confounded by infectious diseases
[20]. In addition, cTnI was preferred in this study due to
lack of expression of cTnI in noncardiac tissue [21]. It is
well known that troponin T isoforms can be released from
noncardiac tissue such as skeletal muscle [22]. In septic
shock, hypoperfusion causes ischaemia in skeletal muscle
and this may consequently lead to false elevation of cTnT
levels.
Myocardial dysfunction is common in patients with sep-
sis. Ver Elst et al. reported that 50% of patients with sepsis
and septic shock had elevated cTnI levels, and 78% of them
had LV dysfunction assessed by echocardiography [23]. In
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suggested as a significant risk factor for myocardial dys-
function and adverse outcomes in septic patients without
ACS [7,8,23–28]. Although its prognostic value in patients
with sepsis has been reported, the underlying mechanism of
cTnI elevation in sepsis is poorly understood. Microinjury
of myocardial cells in sepsis may be attributable to several
factors. These include endotoxins, inflammatory cytokines
or reactive oxygen radicals induced by an infectious process
that may have a direct cardiac myocytotoxic effect. In ad-
dition, inflammatory cytokines such as tumour necrosis-α
and interleukin-1 are reported to be cardiodepressants. My-
ocardial injury due to microvascular thrombosis can also
play a role. It is well known that there is a close relation-
ship between the presence of inflammatory cytokines and
a procoagulant state in patients with severe sepsis [29]. In-
flammatory cytokines, including tumour necrosis factor-α,
interleukin-1β and interleukin-6, are capable of activating
coagulation and inhibiting fibrinolysis, whereas the pro-
coagulant thrombin is capable of stimulating multiple in-
flammatory pathways [30]. In this context, the possibil-
ity of small-vessel thrombosis with subsequent myocardial
microinfarction and troponin release is possible. Taken to-
gether, these findings suggest that sepsis may amplify their
systemic inflammation cascade and aggravate myocardial
ischaemia. In addition, most ESRDpatients are predisposed
to be volume overloaded and hypertensive, resulting in my-
ocardial stretch [16]. This eventually leads to left ventricular
hypertrophy and subsequent cTnI release from injured my-
ocardium even in patients without ACS. Therefore, it can
be speculated that ESRD patients are more susceptible to
myocardial injury that is precipitated by sepsis-associated
tachycardia and anaemia.
Other factors that can potentially contribute to the cTnI
elevation are use of aggressive inotropic agents and severe
hypotensive episode due to septic shock, thus leading to
ischaemic injury to myocardial cells [24]. However, in this
study, inotropics were used only in 24.8% and severe hy-
potensive episodes (systolic blood pressure <90 mmHg)
were observed only in 10% of patients. In addition, septic
shockwas less common in patientswith elevated cTnI levels
(12.0% versus 33.8%, P < 0.05). Therefore, it is unlikely
that such factors are major contributors to the cTnI eleva-
tion. In addition, it has been reported that patients with pre-
vious CVD already have higher serum cTn levels than those
without a history of CVD [31]. We excluded the 33 patients
(27.2%) who experienced CVD prior to the study entry
and reanalysed the data. As a result, the elevation of cTnI
concentrations was a significant predictor of all-cause mor-
tality in a multivariate Cox regression analysis adjusted for
age, diabetes, shock status and CRP levels (data not shown).
One of the confounding factors that can affect cTn levels
is residual renal function. Serum concentrations of cTn are
variable depending on renal impairment, and it is often ele-
vated in patients with CKD who have no evidence of ACS.
However, it has been suggested that its prognostic value
for CVD remains whatever the effect of renal clearance,
although the degree of cTn elevation may be confounded
by renal impairment [32]. This study includes both HD and
PD patients. It is generally acknowledged that residual re-
nal function is more preserved in patients treated with PD.
Therefore, it is possible that cTnI concentrations may differ
according to dialysis modalities and residual renal function
should be considered when interpreting our results. How-
ever, there is no difference in residual renal function be-
tween patients treated with HD and PD and the proportion
of patients receiving HD or PD was not different between
the ET and the LT group. In addition, when analysed ac-
cording to HD and PD patients, respectively, the elevation
of cTnI concentrations still remains as an independent risk
factor for mortality in HD patients as well as PD patients
(data not shown).
In this study, the cut-off value of cTnI was defined as
0.2 ng/ml. This was based on the results of receiver op-
erating curve (ROC) analysis that revealed that this value
provides the best diagnostic accuracy for short-term mor-
tality and long-termmortality compared to the cut-off value
of 0.1 ng/ml. For short- and long-term mortality, the area
under the curve (AUC) when the cut-off value was defined
as 0.2 ng/ml was 0.629 and 0.645, respectively, whereas it
was 0.582 and 0.563 when defined as 0.1 ng/ml. This find-
ingwas also compatible with ROC analysis of the long-term
cardiovascular mortality as AUC with the cut-off value of
0.2 ng/ml was higher compared to that of 0.1 ng/ml (0.675
versus 0.640). However, the prognostic value of cTnI in our
subjects was relatively lower because all AUCs were <0.7.
This can partly be explained by the fact that most deaths
were caused by sepsis itself, not by CVDs.
Several shortcomings in this study should be discussed.
First, this is an observational study with a small sample
size. As per an observational study design, all data were
dependent on medical records, which may not represent
a precise patient status. In addition, a small sample size
may lead to selection bias. Second, echocardiography or
coronary angiography was performed only in small number
of patients; thus we could not provide data pertinent to LV
function and coronary artery status. In addition,we obtained
data for cTnI levels only at two time points because cTnI
levels were not measured serially in the meantime. This
may not reflect a precise change of cTnI levels between
the two periods. However, only six patients experienced
cardiovascular events from the measurement of cTnI to the
study entry and these patients were excluded in the analysis.
Therefore, chances of the elevation of cTnI levels by factors
other than sepsis were minimized. Finally, lower AUC from
the ROC analyses is another shortcoming that may provide
less diagnostic accuracy. Despite these limitations, it should
be noted that elevated cTnI levels in ESRD patients with
sepsis were significantly associated with short- and long-
term mortality in this study.
In conclusion, our findings suggest that in ESRD
patients, sepsis-associated cTnI elevation may have the
predictive value for short- and long-term mortality. There-
fore, elevated cTnI levels in these patients should not be
overlooked and be followed for adverse outcomes.
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